Anbio Biotechnology Operating Income Loss

Quick Answer

Anbio Biotechnology reported Operating Income Loss of $2.00 million for the year ending 2024.

  • Anbio Biotechnology showed an increase of +1.8% in Operating Income Loss from 2023 to 2024.
  • This data is from Anbio Biotechnology's annual report (Form 10-K), filed with the SEC on April 28, 2025.
  • XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2022 to 2024), Anbio Biotechnology's Operating Income Loss has declined by 80.4%.
  • Historical annual values: Fiscal year 2024: $2.00 million | Fiscal year 2023: $1.96 million | Fiscal year 2022: $10.20 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: